Cyclophosphamide Therapy During the Covid19 Pandemic

dc.contributor.authorBitik, B.
dc.contributor.authorOygur, C. S.
dc.contributor.authorKanbur, A. Yalcintas
dc.contributor.authorYucel, A. E.
dc.date.accessioned2024-04-03T13:04:35Z
dc.date.available2024-04-03T13:04:35Z
dc.date.issued2023
dc.identifier.eissn1468-2060en_US
dc.identifier.endpage1880en_US
dc.identifier.issn0003-4967en_US
dc.identifier.issueSupplement 1en_US
dc.identifier.startpage1879en_US
dc.identifier.urihttps://ard.bmj.com/content/annrheumdis/82/Suppl_1/1879.3.full.pdf
dc.identifier.urihttp://hdl.handle.net/11727/11997
dc.identifier.volume82en_US
dc.identifier.wos001107398706266en_US
dc.language.isoengen_US
dc.relation.isversionof10.1136/annrheumdis-2023-eular.6201en_US
dc.relation.journalANNALS OF THE RHEUMATIC DISEASESen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectVasculitisen_US
dc.subjectCOVIDen_US
dc.subjectBest practicesen_US
dc.titleCyclophosphamide Therapy During the Covid19 Pandemicen_US
dc.typeconferenceObjecten_US

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
1879.3.full.pdf
Size:
292.65 KB
Format:
Adobe Portable Document Format
Description:

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: